JP2023502053A - デング病の治療及び予防 - Google Patents

デング病の治療及び予防 Download PDF

Info

Publication number
JP2023502053A
JP2023502053A JP2022528008A JP2022528008A JP2023502053A JP 2023502053 A JP2023502053 A JP 2023502053A JP 2022528008 A JP2022528008 A JP 2022528008A JP 2022528008 A JP2022528008 A JP 2022528008A JP 2023502053 A JP2023502053 A JP 2023502053A
Authority
JP
Japan
Prior art keywords
compound
log
copies
dose
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022528008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502053A5 (https=
Inventor
ゲタルス，オリヴィア，ガブリエラ，エム
ケステルイン，バート，ルドルフ，ロマニー
ストープス，バート，ヘンリ，テレジア
ボンファンティ，ジャン－フランソワ
ヨンカース，ティム，ヒューゴ，マリア
ローク，マルニクス ファン
カプテイン，スザンヌ
ネイツ，ヨハン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Katholieke Universiteit Leuven
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of JP2023502053A publication Critical patent/JP2023502053A/ja
Publication of JP2023502053A5 publication Critical patent/JP2023502053A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022528008A 2019-11-15 2020-11-13 デング病の治療及び予防 Pending JP2023502053A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19209593 2019-11-15
EP19209593.3 2019-11-15
EP19213851.9 2019-12-05
EP19213851 2019-12-05
EP20171172 2020-04-23
EP20171172.8 2020-04-23
PCT/EP2020/082102 WO2021094563A1 (en) 2019-11-15 2020-11-13 Treatment and prevention of dengue disease

Publications (2)

Publication Number Publication Date
JP2023502053A true JP2023502053A (ja) 2023-01-20
JP2023502053A5 JP2023502053A5 (https=) 2023-11-21

Family

ID=73288639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528008A Pending JP2023502053A (ja) 2019-11-15 2020-11-13 デング病の治療及び予防

Country Status (14)

Country Link
US (1) US20220409583A1 (https=)
EP (1) EP4058019A1 (https=)
JP (1) JP2023502053A (https=)
KR (1) KR20220101679A (https=)
CN (1) CN114980884A (https=)
AU (1) AU2020382911A1 (https=)
BR (1) BR112022009199A2 (https=)
CA (1) CA3161338A1 (https=)
IL (1) IL292970A (https=)
MX (1) MX2022005879A (https=)
PH (1) PH12022551160A1 (https=)
TW (1) TW202132269A (https=)
UA (1) UA129409C2 (https=)
WO (1) WO2021094563A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023218285A1 (en) * 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
WO2025248536A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel oxime derivatives to treat viral infections
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515495A (ja) * 2015-05-08 2018-06-14 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての一または二置換インドール誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515495A (ja) * 2015-05-08 2018-06-14 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての一または二置換インドール誘導体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROTEM BEN-SHACHAR ET AL.: "Drivers of Inter-individual Variation in Dengue Viral Load Dynamics", PLOS COMPUTATIONAL BIOLOGY, vol. 12 (11), JPN7024004697, 2016, pages 1005194, ISSN: 0005452636 *
WEI-KUNG WANG ET AL.: "High Levels of Plasma Dengue Viral Load during Defervescence in Patients with Dengue Hemorrhagic Fev", VIROLOGY, vol. 305, JPN7024004698, 2003, pages 330 - 338, ISSN: 0005452635 *
忽那 賢志: "デング熱（Dengue fever）", 感染症クイックリファレンス, JPN7024004700, 2019, ISSN: 0005677431 *
高崎 智彦: "デング熱とは", 国立感染戦研究所 感染症情報, JPN7024004699, 2014, ISSN: 0005677432 *

Also Published As

Publication number Publication date
KR20220101679A (ko) 2022-07-19
UA129409C2 (uk) 2025-04-16
CA3161338A1 (en) 2021-05-20
EP4058019A1 (en) 2022-09-21
TW202132269A (zh) 2021-09-01
US20220409583A1 (en) 2022-12-29
CN114980884A (zh) 2022-08-30
PH12022551160A1 (en) 2023-09-25
WO2021094563A1 (en) 2021-05-20
MX2022005879A (es) 2022-06-14
AU2020382911A1 (en) 2022-06-30
IL292970A (en) 2022-07-01
BR112022009199A2 (pt) 2022-07-26

Similar Documents

Publication Publication Date Title
US20240269125A1 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
JP2023502530A (ja) Ｈｉｖ予防のためのカプシド阻害剤
JP2023502053A (ja) デング病の治療及び予防
JP2021515769A (ja) カプシド集合調節剤の投薬レジメン
AU2014228035B2 (en) Novel dosing regimens of celgosivir for the treatment of dengue
CA2945825C (en) Inhibition of flaviviruses or chikungunya viruses using retinoic acid analogues
KR102568877B1 (ko) 중증열성혈소판감소증후군 치료 또는 예방용 약학 조성물 및 이의 의약 용도
CA2650980A1 (en) Statins for the treatment of viral influenza infections
JP2023502053A5 (https=)
EP4349335A1 (en) Use of 5-nitro-8-hydroxyquinoline
CN102335171B (zh) 一类n-(2-噻唑)苯甲酰胺衍生物的应用
HK40074715A (en) Treatment and prevention of dengue disease
EA049504B1 (ru) Лечение и профилактика лихорадки денге
EA022711B1 (ru) Комбинация дибромида 1,12-додекаметилен-бис-[4-метил-5-(2-гидроксиэтил)тиазолия] и артесуната для лечения тяжелой формы малярии
KR102475176B1 (ko) 정맥내 항바이러스 치료
KR20210129579A (ko) 사스 코로나바이러스 감염증 치료용 약학적 조성물
CN114728006A (zh) 治疗冠状病毒感染的方法
HUT76546A (en) Combinative pharmaceutical compositions and therapy for treating hiv infection
JP2009533428A (ja) 筋肉内抗ウイルス処置
CN114805364B (zh) 四氢吡咯和哌嗪二酮的并环化合物及其制备和在药学上的用途
RU2407738C1 (ru) Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
GB2292081A (en) The use of a Neuraminidase Inhibitor in combination with an Influenza Vaccine
JPWO2003047591A1 (ja) 肺高血圧症予防治療剤
KR20210129613A (ko) 사스 코로나바이러스 감염증 치료용 약학 조성물 및 이의 의약 용도
JP2024533532A (ja) コロナウイルス感染症を処置するための新規の併用薬物、医薬組成物およびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250902